BSE Live
Mar 20, 16:01Prev. Close
1238.65
Open Price
1248.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:58Prev. Close
1239.20
Open Price
1250.00
Bid Price (Qty.)
1256.40 (31)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Cipla (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 14.71 | 17.29 | 18.77 | 14.00 | 11.96 | |
| Diluted EPS (Rs.) | 14.66 | 17.29 | 18.77 | 14.00 | 11.96 | |
| Cash EPS (Rs.) | 20.10 | 21.32 | 22.55 | 17.51 | 15.05 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 138.01 | 125.58 | 110.36 | 93.93 | 82.25 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 138.12 | 125.69 | 110.47 | 94.04 | 82.36 | |
| Dividend / Share(Rs.) | 2.00 | 2.00 | 2.00 | 2.00 | 2.80 | |
| Revenue from Operations/Share (Rs.) | 126.18 | 116.83 | 102.16 | 86.90 | 78.85 | |
| PBDIT/Share (Rs.) | 26.27 | 28.27 | 29.25 | 21.55 | 17.59 | |
| PBIT/Share (Rs.) | 20.87 | 24.24 | 25.47 | 18.04 | 14.50 | |
| PBT/Share (Rs.) | 19.18 | 22.65 | 25.06 | 17.70 | 14.34 | |
| Net Profit/Share (Rs.) | 14.71 | 17.29 | 18.77 | 14.00 | 11.96 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 20.81 | 24.19 | 28.62 | 24.79 | 22.30 | |
| PBIT Margin (%) | 16.54 | 20.74 | 24.93 | 20.75 | 18.39 | |
| PBT Margin (%) | 15.19 | 19.38 | 24.52 | 20.37 | 18.18 | |
| Net Profit Margin (%) | 11.65 | 14.80 | 18.37 | 16.10 | 15.16 | |
| Return on Networth / Equity (%) | 10.65 | 13.76 | 17.00 | 14.90 | 14.54 | |
| Return on Capital Employed (%) | 10.17 | 13.21 | 16.33 | 14.38 | 14.02 | |
| Return on Assets (%) | 7.77 | 10.74 | 13.11 | 12.49 | 11.36 | |
| Total Debt/Equity (X) | 0.12 | 0.09 | 0.11 | 0.00 | 0.07 | |
| Asset Turnover Ratio (%) | 66.69 | 72.58 | 71.36 | 77.58 | 74.94 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.83 | 2.11 | 3.02 | 4.07 | 2.84 | |
| Quick Ratio (X) | 0.91 | 1.07 | 1.98 | 2.52 | 1.66 | |
| Inventory Turnover Ratio (X) | 3.08 | 3.74 | 3.50 | 3.82 | 3.36 | |
| Dividend Payout Ratio (NP) (%) | 13.59 | 11.56 | 10.65 | 14.28 | 23.40 | |
| Dividend Payout Ratio (CP) (%) | 9.94 | 9.37 | 8.87 | 11.42 | 18.60 | |
| Earnings Retention Ratio (%) | 86.41 | 88.44 | 89.35 | 85.72 | 76.60 | |
| Cash Earnings Retention Ratio (%) | 90.06 | 90.63 | 91.13 | 88.58 | 81.40 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 58,403.65 | 31,638.57 | 31,350.87 | 24,409.46 | 26,133.60 | |
| EV/Net Operating Revenue (X) | 5.76 | 3.37 | 3.82 | 3.50 | 4.13 | |
| EV/EBITDA (X) | 27.69 | 13.94 | 13.35 | 14.11 | 18.50 | |
| MarketCap/Net Operating Revenue (X) | 5.64 | 3.28 | 3.72 | 3.50 | 4.07 | |
| Retention Ratios (%) | 86.40 | 88.43 | 89.34 | 85.71 | 76.59 | |
| Price/BV (X) | 5.15 | 3.06 | 3.44 | 3.24 | 3.90 | |
| Price/Net Operating Revenue | 5.64 | 3.28 | 3.72 | 3.50 | 4.07 | |
| Earnings Yield | 0.02 | 0.05 | 0.05 | 0.05 | 0.04 |
19.03.2026
04.03.2026
Cipla to form JV with Kemwell Biopharma; share price down marginally
04.03.2026
23.02.2026
27.01.2026
Cipla Consolidated December 2025 Net Sales at Rs 7,074.48 crore, up 0.02% Y-o-Y
27.01.2026
Cipla Standalone December 2025 Net Sales at Rs 4,498.08 crore, down 9.51% Y-o-Y
10.11.2025
Cipla Standalone September 2025 Net Sales at Rs 5,225.72 crore, up 9.44% Y-o-Y
03.11.2025
Cipla Consolidated September 2025 Net Sales at Rs 7,589.44 crore, up 7.64% Y-o-Y
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
09.05.2024
17.04.2024
Cipla Q4 PAT may dip 24.9% YoY to Rs 869.4 cr: ICICI Securities
12.07.2023
28.01.2025
30.10.2024
Multiple near-term challenges may hijack Cipla's growth trajectory
13.05.2024
06.11.2018
Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
20.03.2026
19.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth